Last reviewed · How we verify
Midazolam load
Midazolam is a benzodiazepine that enhances inhibitory GABA neurotransmission in the central nervous system to produce sedation, anxiolysis, and amnesia.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation and anxiolysis. Used for Sedation and anxiolysis in perioperative settings, Acute seizure management, Procedural sedation.
At a glance
| Generic name | Midazolam load |
|---|---|
| Also known as | Versed |
| Sponsor | University of Pennsylvania |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Sedation, Anxiety |
| Phase | FDA-approved |
Mechanism of action
Midazolam binds to benzodiazepine receptors on GABA-A channels, increasing chloride influx and hyperpolarizing neurons, thereby reducing neuronal excitability. This results in rapid onset sedation and anxiolysis. The 'load' formulation refers to an initial bolus dosing strategy, commonly used in acute care settings such as procedural sedation or critical care.
Approved indications
- Procedural sedation and anxiolysis
- Acute agitation and anxiety in critical care settings
- Induction of general anesthesia
Common side effects
- Respiratory depression
- Hypotension
- Oversedation
- Paradoxical agitation
- Amnesia
Key clinical trials
- Propofol vs Remifentanil for Sedation in Gastroscopy (NA)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Attenuate the Stress Response in Laparoscopic Cholecystectomy (PHASE4)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
- Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants (PHASE3)
- Comparison of Effect of Dexmedetomidine and Midazolam on Emergence Agitation (NA)
- Dexmedetomidine and Myocardial Protection (NA)
- Effect of Dexmedetomidine on Tear Production in Angioplasty Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam load CI brief — competitive landscape report
- Midazolam load updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI